BioSpace News Archive

BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the development of investigational therapeutics for patients with genetically driven cancers.

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that it has augmented its 2020 Annual Report with the provision of its inaugural Sustainability Report for the period which includes the Company’s environmental, social and governance (ESG) priorities.

Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today provided a clinical program update for its lead program, ADAIR, a proprietary abuse-deterrent formulation of immediate-release (IR

This Pre-Series A Funding will accelerate the growth of ImpriMed’s AI-powered predictive tool that identifies which anti-cancer drugs are most likely to be effective for a particular dog’s lymphoma or leukemia

Nasus Pharma Ltd, a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based Intranasal specialized product portfolio to address acute medical conditions & public health threats, announced positive results from a pivotal trial of intranasal powder-based Naloxone.

Incyte announced that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 4, 2021.

With Lyme disease season breaking out across the United States, Quidel Corporation announced today that it has partnered with the Bay Area Lyme (BAL) Foundation to help heighten public awareness to this alarming health condition that afflicts as many as 400,000 Americans each year. Quidel is the nation’s leading developer of rapid Lyme disease testing.

Waters Corporation (NYSE:WAT) and Genovis AB (Nasdaq First North Growth Market) are formally collaborating to develop and market complete routine biopharmaceutical characterization workflows based on the Waters™ BioAccord™ LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes™.

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, today announced that long-term survival data from the CENTAUR trial of AMX0035 in patients with ALS were selected for an oral presentation in the Contemporary Clinical Issues Plenary Session on April 19 at the 2021 American Academy of Neurology (AAN) Annual Meeting.

EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies Nabiximols data show efficacy and safety results in patients with spasticity associated with multiple sclerosis